EMA — authorised 14 December 2012
- Application: EMEA/H/C/002259
- Marketing authorisation holder: Merck Sharp and Dohme Ltd.
- Local brand name: Jenzyl
- Indication: TReament of metastatic soft tissue sarcoma or bone sarcoma
- Status: withdrawn
EMA authorised Jenzyl on 14 December 2012
Yes. EMA authorised it on 14 December 2012.
Merck Sharp and Dohme Ltd. holds the EU marketing authorisation.